TOP November 2015 Vol 8 No 4
In the November issue of The Oncology Pharmacist, we provide a highlight of a recent study that was presented at the 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on Supportive Care in Cancer on the use of docetaxel plus nintedanib in patients with non–small-cell lung cancer (NSCLC)
With the surge in new immunotherapies becoming available for the treatment of melanoma, non-small-cell lung cancer (NSCLC), bladder cancer, and other solid tumors, it is important to know how to assess response patterns that differ from those of chemotherapy, manage the unique side effects, and understand the mechanisms of action of these drugs.
Second-Line Treatment with Ramucirumab After First-Line Sorafenib for Advanced Hepatocellular Carcinoma
Hepatocellular carcinoma is the second most common cause of cancer-related death and occurs most often in patients with cirrhosis. Vascular endothelial growth factor (VEGF) plays an important role in tumor growth and angiogenesis, and is overexpressed in patients with hepatocellular carcinoma.
Boston, MA-What is the best chemotherapy regimen to use for patients with locally advanced nonsquamous non-small-cell lung cancer (NSCLC)? The phase 3 PROCLAIM trial attempted to answer this question, but the study failed to determine the best regimen for this patient population.
Washington, DC-The role of oncology specialty pharmacy in helping to streamline medication delivery for patients with cancer was the subject of a panel discussion that took place at the Fifth Annual Conference of the Association for Value-Based Cancer Care.
Ibrance (Palbociclib): First CDK4 and CDK6 Inhibitor FDA Approved for the Treatment of Postmenopausal Women with Metastatic Breast Cancer
Austin, TX-Three advanced azole agents are now being used to treat invasive aspergillosis, and strengths and weaknesses exist for each of them, according to research presented by James S. Lewis II, PharmD, at the 11th annual Hematology/Oncology Pharmacy Association conference.
Boston, MA-Rociletinib, a specially engineered third-generation EGFR inhibitor, is accumulating an impressive track record in early studies of non-small-cell lung cancer (NSCLC). The drug is specifically designed for use in patients with NSCLC and the T790M mutation, a heretofore patient population with unmet needs. T790M, the most common mutation associated with resistance to first-line EGFR-directed tyrosine kinase inhibitor (TKI) therapy, is present in 60% of patients with resistance to TKIs.
Page 1 of 2
Results 1 - 10 of 20
Results 1 - 10 of 20